AlzeCure Pharma AB (SE:ALZCUR)

:ALZCUR

ALZCUR

AlzeCure Pharma AB

RESEARCH TOOLSreports

Want to see SE:ALZCUR full AI Analyst Report?

AlzeCure Pharma AB (ALZCUR) Price & Analysis

0 Followers

ALZCUR Stock Chart & Stats

kr2.44

kr0.16(7.05%)

At close: Mar 06 4:00 PM EST

kr2.44

kr0.16(7.05%)

Day’s Range― - ―

52-Week Rangekr1.14 - kr5.69

Previous CloseN/A

Volume72.39K

Average Volume (3M)52.87K

Market Cap

kr541.94M

Enterprise Valuekr453.76M

Total Cash (Recent Filing)kr50.34M

Total Debt (Recent Filing)kr5.12M

Price to Earnings (P/E)―

Beta-0.36

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.45

Shares Outstanding137,897,340

10 Day Avg. Volume28,042

30 Day Avg. Volume52,872

Financial Highlights & Ratios

PEG Ratio-1.96

Price to Book (P/B)6.11

Price to Sales (P/S)0.00

P/FCF Ratio-5.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.35

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Modest DebtThe company’s very low debt and 0.16 debt-to-equity ratio provide durable financial flexibility for an R&D-stage biotech. Low interest burden preserves cash for trials and partnering efforts, reducing near-term solvency risk and supporting the ability to withstand multi-year development cycles.

Focused CNS R&D PlatformsA focused R&D platform in CNS builds a structural competitive advantage: domain expertise and repeatable discovery processes increase probability of generating licensable candidates. Specialization attracts partners seeking CNS assets and supports multiple monetization pathways over the medium term.

Improving Cash-flow TrendAn improving free cash flow swing signals operational or financing progress that can extend runway. While still negative, a trend toward lower cash burn is durable if sustained, reducing frequency and size of equity raises and improving ability to fund key clinical milestones or partnering activities.

Bears Say

No Revenue And Widening Net LossAbsence of product revenue and a materially larger net loss undermine self-funding capacity and highlight the long path to commerciality. Persistent negative earnings weaken internal cash generation and increase structural reliance on external financing or partnerships to sustain R&D programs.

Consistent Negative Operating Cash FlowSustained negative operating cash flow indicates ongoing cash burn from R&D and operations. This durable drain constrains strategic optionality, forces periodic capital raises, and heightens execution risk if financing windows narrow during critical clinical development stages.

Equity Erosion And Dilution RiskSignificant decline in equity over several years reflects cumulative losses and raises the prospect of further dilution to fund operations. Persistent capital erosion can impair investor returns, reduce financial cushions, and make future financing more dilutive or costly for long-term shareholders.

ALZCUR FAQ

What was AlzeCure Pharma AB’s price range in the past 12 months?

AlzeCure Pharma AB lowest stock price was kr1.14 and its highest was kr5.69 in the past 12 months.

What is AlzeCure Pharma AB’s market cap?

AlzeCure Pharma AB’s market cap is kr541.94M.

When is AlzeCure Pharma AB’s upcoming earnings report date?

AlzeCure Pharma AB’s upcoming earnings report date is Aug 26, 2026 which is in 58 days.

How were AlzeCure Pharma AB’s earnings last quarter?

AlzeCure Pharma AB released its earnings results on May 05, 2026. The company reported -kr0.165 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.165.

Is AlzeCure Pharma AB overvalued?

According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AlzeCure Pharma AB pay dividends?

AlzeCure Pharma AB does not currently pay dividends.

What is AlzeCure Pharma AB’s EPS estimate?

AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AlzeCure Pharma AB have?

AlzeCure Pharma AB has 137,897,340 shares outstanding.

What happened to AlzeCure Pharma AB’s price movement after its last earnings report?

AlzeCure Pharma AB reported an EPS of -kr0.165 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.049%.

Which hedge fund is a major shareholder of AlzeCure Pharma AB?

Currently, no hedge funds are holding shares in SE:ALZCUR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AlzeCure Pharma AB

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. The company was founded in 2012 and is based in Huddinge, Sweden.